Annual report pursuant to Section 13 and 15(d)

REVENUES FROM CONTRACTS AND SIGNIFICANT CUSTOMERS (Tables)

v3.23.1
REVENUES FROM CONTRACTS AND SIGNIFICANT CUSTOMERS (Tables)
12 Months Ended
Dec. 31, 2022
REVENUES FROM CONTRACTS AND SIGNIFICANT CUSTOMERS  
Schedule of disaggregation of net revenues

    

Year Ended December 31, 

($ in thousands)

    

2022

    

2021

Qbrexza®

$

26,715

$

17,056

Accutane®

18,373

10,053

Targadox®

7,972

22,378

Amzeeq®

7,242

Ximino®

 

4,957

 

8,247

Zilxi®

 

2,273

 

Exelderm®

 

3,463

 

5,363

Other branded revenue

 

 

37

Total product revenues

$

70,995

$

63,134

Schedule of other revenue

    

Year Ended December 31,

($in thousands)

2022

    

2021

Other revenue

 

$

2,674

$

Total other revenue

$

2,674

$